AU2004326111A1 - Process for preparing 5,6-dihydro-4-(S)-(ethylamino)-6-(S) methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide HCI - Google Patents

Process for preparing 5,6-dihydro-4-(S)-(ethylamino)-6-(S) methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide HCI Download PDF

Info

Publication number
AU2004326111A1
AU2004326111A1 AU2004326111A AU2004326111A AU2004326111A1 AU 2004326111 A1 AU2004326111 A1 AU 2004326111A1 AU 2004326111 A AU2004326111 A AU 2004326111A AU 2004326111 A AU2004326111 A AU 2004326111A AU 2004326111 A1 AU2004326111 A1 AU 2004326111A1
Authority
AU
Australia
Prior art keywords
solvent
formula
group
organic solvent
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004326111A
Inventor
Madhusudan Nagorao Deshmukh
Mukund Keshao Gurjar
Sanjay Janardhan Naik
Tushar Anil Naik
Santoshpratap Pardeshi
Vincent Paul
Dhananjaygovind Sathe
Venkatasubramaniam Radhakrishnan Tarur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Council of Scientific and Industrial Research CSIR
Original Assignee
Council of Scientific and Industrial Research CSIR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council of Scientific and Industrial Research CSIR filed Critical Council of Scientific and Industrial Research CSIR
Publication of AU2004326111A1 publication Critical patent/AU2004326111A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

WO 2006/070387 PCT/IN2004/000420 PROCESS FOR PREPARING 5,6-DIHYDRO-4-(S)-(ETHYLAMINO)-6-(S) METHYL -4H-THIENO[2,3b]THIOPYRAN-2-SULPHONAMDE-7,7-DIOXIDE HCl Field of the invention The present invention relates to an improved process for the preparation of 5,6 dihydro-4-(S)-(ethylamino)-6-(S)methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7 dioxide hydrochloride commonly known as Dorzolamide Hydrochloride. This compound is described in US Patent 4,797,413 as an agent to reduce intraoccular pressure by inhibiting carbonic anhydrase enzyme. NHl HCl S S SO 2 NH2 0 0 (1) Background of the invention A process for the preparation of Dorzolamide Hydrochloride and its derivatives is known. US Patent 5,688,968 describes preparation of Dorzolamide HCl starting from chiral 5,6-dihydro-4-(S)-hydroxy-6-(S)-methyl-4H-thiopyran-7,7-dioxide, as depicted in scheme 1: Scheme 1: 0 0 OH NH NH R S SS R S S R SO2Cl 0 0 0 -0 0 0 1 11 111 fl- H NTH [H R S 1S S0 2
NH
2 R S O 0S S0 2
NH
2 0R//I)I\\I0IL S 2
NH
2 0 0V 1Vv iv The process described in EP 0 296 879 (equivalent of US 4,797,413) is of particular relevance. EP 0 296 879 describes the synthesis of Dorzolamide Hydrochloride starting from thiophene-2-thiol as depicted in scheme 2 and 3 WO 2006/070387 PCT/IN2004/000420 Scheme 2 0 0 0 OH HS I. J I b. R SO R S S R S S S0 2 0H Vii Viii ix x O0 OH R S S SO 2 C1 R S SO 2 NH, R Ss SO 2 NH, xi xii x 0 OH R~~k SON2RS2H2RS S2H HNH s s 2 NH2 R 2NH2 xvxv OH NNH SHCI RIO SO2LH2 R OSS0NH O Rh O2NH2 SONH O Xvii (1) Scheme 3 OH NH NH The pr s d e n E s (s 2
NH
2 Efll S daS 2
NH
2 d iv n i Xvii N~H - CI (I) The process described in EP 0,296,879 (scheme 2) has the following disadvantages: (a) The starting material Thiophene-2-thiol is unstable and undergoes oxidation to form disulfide, leading to lower yield of viii; (b) the yield of sulfonamide (xii) from sulphonic acid (x) is very poor (35%) and requires use of 1 8-crown-6 ether, which is expensive; (c) oxidation of alcohol (xiii) to sulfone is carried out using oxone which is expensive and hazardous; and separation of cis/trans isomer is done by column chromatography which is industrially inconvenient. 2 WO 2006/070387 PCT/IN2004/000420 Objective of the Invention: The object of present invention is to provide an improved process for commercial manufacture of 5,6-dihydro-4-(S)-(ethylamino)-6-(S)methyl-4H-thieno[2,3b]thiopyran-2 sulphonamide-7,7-dioxide hydrochloride commonly known as Dorzolamide Hydrochloride starting from stable 2-bromo thiophene. Another object of the invention is to provide an improved process for Dorzolamide hydrochloride preparation, which is less time consuming involving fewer steps and increases the product efficiency. Another object of the invention is to provide a process for Dorzolamide hydrochloride manufacture, which avoids use of expensive catalyst. Another object of the invention is to provide a process for Dorzolamide hydrochloride manufacture, which avoids the use of expensive reagents. Another object of the invention is to provide a process for Dorzolamide hydrochloride manufacture, which is industrially feasible. Summary of the invention Accordingly, the present invention provides a process for preparing 5,6-dihydro-4 (S)-(ethylamino)-6-(S)methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide hydrochloride of formula (I), NH HCI S OS S0 2 NH2 (I) the process comprising (a) reacting compound of formula II wherein X is halo, with magnesium metal and treating the generated Grignard reagent in a solvent in situ with sulfur, triethyl amine hydrochloride, crotonic acid and suitable base to obtain compound of formula III, 0 0 x s ss II I (b) reacting compound of formula III with a chlorinating agent to obtain a acid chloride, followed by subjecting the acid chloride to cyclisation in the presence of a Lewis acid to obtain a compound of formula IV; 3 WO 2006/070387 PCT/IN2004/000420 S S IV (c) reacting compound of formula IV with a mixture of chlorosulphonic acid and a chlorinating agent to form a sulphonylchloride of formula XX, extracting the sulphonyichloride in a chlorinated solvent, washing with water, drying and evaporating the chlorinated solvent to obtain compound of formula V; 0 0 s s 02C1 S soS2NH2 XX V (d) reducing compound of formula V to obtain compound of formula VI; OH S S SO 2
NH
2 VI (e) oxidising compound of formula VI to obtain compound of formula VII; OH O S
SO
2
NH
2 VII (f) subjecting compound of formula VII to a Ritter reaction to obtain compound of formula VIII 0 NH O S O S
SO
2
NH
2 VII 4 WO 2006/070387 PCT/IN2004/000420 (g) reducing compound of formula VIII to obtain compound of formula IX NH S\\ S
SO
2
NH
2 IX (h) converting compound of formula IX to acid addition salt thereof of formula XXI and recrystallizing enriched salt from the solvent and then converting salt of formula XXI to compound of formula X NH NH S S SO 2
NH
2 OS S SO 2 NH2 XXI X (i) resolving compound of formula X into compound of formula I. In one embodiment of the invention, in step (a), the organic solvent is selected from the group consisting of ethers, cyclic ethers and aromatic hydrocarbon. In another embodiment of the invention, the organic solvent used in step (a) is tetrahydrofuran. In yet another embodiment of the invention, step (a) is carried out in the presence of a base selected from the group consisting of organic alkylamine and pyridine. In a further embodiment of the invention, the base is trialkyl amine. In a preferred embodiment, the base is triethyl amine. In another embodiment of the invention, in compound of formula II, X is a halo selected from the group consisting of Cl, Br and I. In another embodiment of the invention, step (a) is carried out at a temperature in the range of O'C to 70*C. In another embodiment of the invention, in step (b), the organic solvent is an aprotic non-polar solvent. In another embodiment of the invention, the aprotic non-polar solvent used is a chlorinated solvent such as MDC. In another embodiment of the invention, the Lewis acid is selected from the group consisting of AlCl 3 , ZnCl 2 and SnCl 4 and more preferably SnCl 4 . 5 WO 2006/070387 PCT/IN2004/000420 In another embodiment of the invention, sulfonyl chloride of formula XX is dissolved in an organic solvent selected from the group consisting of ether and ketone. In a further embodiment of the invention, the organic solvent is tetrahydrofuran. In another embodiment of the invention, the sulfonyl chloride of formula XX is dissolved in an organic sovlent and then treated with ammonia followed by chlorination with a chlorinating agent selected from the group consisting of POC 3 , PC 5 , PC 3 , SOCI 2 and more preferably SOCl 2 and in the presence of a chlorination solvent selected from the group consisting of CHC1 3 , MDC, and EDC, preferably MDC. In another embodiment of the invention, in step (d) reduction is effected using sodium borohydride in the presence of a solvent and at a temperature in the range of 0C to 40*C. In a further embodiment of the invention, the solvent is a lower aliphatic alcohol and more preferably methanol. In another embodiment of the invention, in step (e) compound of formula VI is oxidised with sodium perborate in presence of acetic acid at 20'C to 70"C. In another embodiment of the invention, in step (f) the Ritter reaction of compound of formula VII is effected in a strong acid with acetonitrile at 10*C to 40*C. In a further embodiment of the invention, the strong acid is selected from the group consisting of sulfuric acid and a mixture of concentrated sulfuric acid and fuming sulfuric acid. In another embodiment of the invention, in step (g), reduction is effected using borane dimethylsulfide complex in an organic solvent selected from ether and cyclic ether. In a further embodiment of the invention, the organic solvent used in step (g) is tetrahydrofuran. In another embodiment of the invention, in step (h), the organic solvent is selected from the group consisting of a ketone, an ester, a dipolar aprotic solvent, lower aliphatic alcohol, aliphatic hydrocarbon and aromatic hydrocarbon. In a further embodiment of the invention, the ester is ethyl acetate. In a further embodiment of the invention, the acid used for salt formation in step (h) is a mineral acid selected from the group consisting of HCl, H 2 S0 4 , HN0 3 , and HBr more preferably HCl dissolved in a lower aliphatic alcohol. In a further embodiment of the invention, the acid used for salt formation in step (h) is ethanolic HCl. In another embodiment of the invention, the organic solvent used for recrystallization is selected from the group consisting of a ketone, an ester, a dipolar aprotic solvent, lower 6 WO 2006/070387 PCT/IN2004/000420 aliphatic alcohol, aliphatic hydrocarbon or aromatic hydrocarbon, preferably an ester, lower aliphatic alcohol or mixture thereof, more preferably ethyl acetate, ethanol or mixture thereof In a further embodiment of the invention, the compound of formula X is rsolved using di-p-toluyl-L-tartarate and di-p-toluyl-D-tartarate. Detailed description of the invention The invention provides a process for preparing 5,6-dihydro-4-(S)-(ethylamino)-6 (S)methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide hydrochloride of formula (I), comprising of nine steps, as depicted in scheme 4 below: Scheme 4 0 0 0 OHO 0 -(S S S S SONH-1 II IIIV V 0 OH OH NH S S S0 2
NH
2 S \ S SO 2 NH2 s S SO 2 NH2 VI VII VIII NH NH NH HX HCl so 2 S\\ 4 IY i1NH2 SOiNH2 01SO 2
NH
2 ix x (I) Step I: Preparation of compound of formula III by reacting compound of formula II with magnesium metal followed by treatment of thus generated Grignard reagent in a solvent in situ with sulfur, triethyl amine hydrochloride, crotonic acid and suitable base at 0*C to 70*C as shown in scheme 5, Scheme 5: 0 i.S Mg ii.TEA.HCl OH X SKC XMg S 2 ... J S ill COOH S S iv.Base II xviii III 7 WO 2006/070387 PCT/IN2004/000420 X of formula II is a halo -Cl, -Br, -I preferably -Br. The organic solvents are ethers, cyclic ethers and aromatic hydrocarbon but preferably cyclic ethers and more preferably THF. The base is an organic alkylamine or pyridine, preferably trialkyl amine and more preferably triethyl amine. Step H: Preparation of compound of formula IV by reacting compound of formula III with chlorinating agent followed by cyclisation of acid chloride of formula XIX generated in-situ in presence of Lewis acid in a solvent at O*C to 40*C as shown in scheme 6. Scheme 6 0 0 0 OH C S SnC Cl Sn Sl III XIX IV The organic solvents are aprotic non-polar solvents, preferably chlorinated solvents and more preferably MDC. Lewis acids are AICl 3 , ZnCl 2 , SnCl 4 and more preferably SnCl 4 . Step III: Preparation of compound of formula V by reacting compound of formula IV with mixture of chlorosulphonic acid and chlorinating agent at -10'C to 10*C, extracting thus formed sulphonylchloride of formula XX in a chlorinated solvent, washing with water, drying and evaporating the chlorinated solvent. Dissolving the sulfonyl chloride of formula XX in suitable organic solvents followed by treatment with ammonia as shown in scheme 7 Scheme 7: S lOS3H NH 4 0H s s fi. SOC1 2 S S So 2 Cij s s So 2 M1 2 IV XX V The chlorination agent is selected from POCl 3 , PCl 5 , PCl 3 , SOC1 2 and more preferably SOCl 2 . Chlorination solvents are preferably selected from CHC1 3 , MDC, and EDC, more preferably MDC. The organic solvent for dissolving sulfonyl chloride is an ether or a ketone, preferably ether and more preferably THF. 8 WO 2006/070387 PCT/IN2004/000420 Step IV: Preparation of compound of formula VI by reducing compound of formula V with sodium borohydride in presence of solvent at 0*C to 40*C as shown in scheme 8. Scheme 8 0 OH NaBH 4 S S SO 2
NH
2 S SO NH V VI The organic solvent is lower aliphatic alcohol and more preferably methanol. Step V: Preparation of compound of formula VII by oxidizing compound of formula VI with sodium perborate in presence of acetic acid at 20*C to 70*C as shown in scheme 9. Scheme 9 OH OH NaBO 3 S S SO 2
NH
2 O- S+O S SO2NH2 VI VII Step VI: Preparation of compound of formula VIII by Ritter reaction of compound of formula VII in strong acid with acetonitrile at 10*C to 40*C as shown in scheme 10. Scheme 10 H i.CH 3 CN S S SO 2
NH
2 ii H 2
SO
4 S S SO 2
NH
2 VII VII 9 WO 2006/070387 PCT/IN2004/000420 The strong acids are concentrated sulfuric acid or mixture of concentrated sulfuric acid and fuming sulfuric acid. Step VH: Preparation of compound of formula IX by reducing compound of formula VIII with borane dimethylsulfide complex in organic solvents. As shown in scheme 11 Scheme 11 0 NHH
BH
3 DMS o S S
SO
2
NH
2 O S \ S S0 2 NH2 VIII IX The organic solvents are ethers, cyclic ethers, preferably cyclic ethers and more preferably THE. Step VIII: Preparation of compound of formula X by converting the compound of formula IX to its acid addition salt in a solvent followed by recrystallisation of the enriched salt from an organic solvent or a mixture of solvents as shown in scheme 12. The organic solvent is a ketone, an ester, a dipolar aprotic solvent, lower aliphatic alcohol, aliphatic hydrocarbon or aromatic hydrocarbon, preferably an ester and more preferably ethyl acetate. The acid used for salt formation is a mineral acid like HCl, H 2
SO
4 , HNO 3 , HBr more preferably HCl dissolved in lower aliphatic alcohol preferably ethanol. The acid used for salt formation is most preferably ethanolic HCl. The organic solvent for recrystallization is a ketone, an ester, a dipolar aprotic solvent, lower aliphatic alcohol, aliphatic hydrocarbon or aromatic hydrocarbon, preferably an ester, lower aliphatic alcohol or mixture thereof, more preferably ethyl acetate, ethanol or mixture thereof Scheme 12 NH NH .S S S 2
NH
2 o2
SO
2
NH
2 0 S SO2NH2 2 S IX xxi X 10 WO 2006/070387 PCT/IN2004/000420 Step IX: Preparation of compound of formula I by resolution of compound of formula X using di-p-toluyl-L-tartarate and di-p-toluyl-D-tartarate. The process of manufacturing Dorzolamide hydrochloride by the present invention comprises use of 2-bromo thiophene as a starting material avoiding use of unstable thiophene-2-thiol. The process of the said invention requires less number of steps since sulfonamide of formula IV is prepared directly from compound of formula III avoiding isolation of sulfonic acid X. This eliminates the use of an expensive catalyst. The process of invention uses cheap, commercially available sodium perborate as an oxidizing agent, thus making the process more economical. The process of the said invention makes use of hydrochloride salt formation as a means to separate cis:trans isomer thus avoiding industrially cumbersome column chromatography. Experimental: Example 1: Preparation of (RS).3-(2-mercaptothiophene)butanioc acid(III) To a mechanical stirred mixture of magnesium turnings (20 gm, 0.833 moles) in THF (700 ml), crystal of iodine and 2-bromo thiophene (II) (5.0 gm 0.0305 mole) were added to initiate reaction. Once reaction was initiated, 2-bromo thiophene (95 gm 0.58 mole) was added to maintain reflux which was then continued for 2 hrs then cooled to 45*C. Sulfur (19.66 gm, 0.614 mole) was then added maintaining temp. below 50*C and stirring continued for 2 hrs. Triethyl amine hydrochloride (84 gm, 0.611 mole) was then added at 45*C and stirring continued for 1 hrs. A mixture of triethyl amine (80 gm, 0.79 mole) and crotonic acid (63gm, 0.733 mole) in THF (200 ml) was then added at 45*C. The mixture was refluxed for 18 to 20 hrs. pH was adjusted to 2 to 2.5 by 6 N HCl at 0* to 15"C. The compound of formula (III) was extracted with MDC and concentrated to dryness to gave title compound (123 gm, 100%). 'H NMR (CDCl3 ) 8 1.35 (d, 3H, J=6.9Hz, CH3 ) 2.48 ( dd, 1H, J=8.0 J=16.1 Hz, CH2 ) 2.77 (dd, 1H, J=6.4 J=16.1 Hz, CH 2 ) 3.36-3.42 (im, 1H,CH) 7.03 (dd, 1H, J=3.4 J=5.3 Hz, 3-H) 7.20 (dd,1H, J=1.2 J=3.4Hz,4-H ) 7.43 ( dd,1H, J=1.2Hz, J=5.3Hz, 2-H ) Example 2: Preparation of 5,6 dihydro-4H-6-methylthieno[2,3-b]thiopyran-4-one (IV) To a solution of product from example 1 (123 gm 0.609 mole) in MDC (1845 ml) and DMF (10 ml) thionyl chloride (54.35 ml, 0.73 mole) was added dropwise and mixture stirred at reflux temperature of 37 to 40'C for 2 hrs. The mixture was cooled to -10*C and a solution of SnCl 4 (39.12 ml, 0.33 moles) in MDC was added dropwise maintaining temperature below 0*C. The reaction was stirred at 0*C for 1 hr, and water (500 ml) was then added dropwise 11 WO 2006/070387 PCT/IN2004/000420 while maintaining temperature below 10*C. The layers were separated. The aqueous phase was extracted with MDC and organic layers were washed with water followed by saturated bicarbonate solution, finally with brine. MDC layer was then stirred with silica gel (100 gm), filtered and washed by MDC. Organic layer was dried with anhydrous sodium sulphate. Finally.organic layer was concentrated completely to get title compound (91 gm, 81.1%) 'H NMR ( CDCl3 ) 5 1.48 (d, 3H, J=6.9Hz, CH 3 ) 2.69 (dd, 1H, J=11.4 J=16.8Hz, CH 2 ) 2.88 (dd,1H, J=3.2 J=16.8Hz, CH 2 ) 3.80 ( t,1H, CH) 7.01 ( d,1H, J=5.5Hz, 3-H ) 7.46 (d, 1H, J=5.5Hz, 2-H) Example 3: Preparation of 5,6 dihydro-4H-6-methylthieno[2,3-b]thiopyran-4-one-2 sulfonamide(V) To stirred solution of chlorosulphonic acid (196.9 ml, 2.96 mole), thionyl chloride (71.67 ml, 0.987 mole) was added slowly at temperature O'C to 10*C. The mixture was stirred at a temperature of 30*C to 32*C for 3 hrs and then cooled to O'C. Compound prepared in Example 2 (91 gm, 0.494 Mole) was slowly added at temperature of O'C to 5*C. The mixture was then stirred at temperature of 0 to 5*C for 1 hr and the temperature then raised to 25 to 30*C and maintained for 5 to 10 hrs. MDC (1000 ml) was then added and the reaction mass was quenched using 700 gm of ice below temperature of 20'C. The lower organic layer was separated. The aqueous layer was extracted with MDC and mixed to main organic layer which is washed with chilled water. The organic layer was concentrated to get a sticky mass (130 gm) which was then dissolved in THIF (100 ml), to which was added to (150 ml) chilled liquor ammonia. This was stirred for 2 hrs and ice water (2000 ml) added. This was further stirred for 3 hrs and filtered and washed with water, and dried to get title compound (V) (65 gm, 50 %). 'H NMR ( DMSO d-6 ) 8 1.51 (d, 3H, J=6.9Hz,CH 3 ) 2.70 ( dd,1H, J=11.4 J=16.8Hz, CH 2 ) 2.93 (dd, 1H, J=3.2 J=16.8Hz, CH 2 ) 3.80-4.0 (bm,1H, CH ) 4.62-4.80 (bm,1H,CH ) 7.32 (bs,2H,NH 2 ) 7.84 ( d,1H,J=5.5Hz,3- H) Example 4: Preparation of 5,6 dihydro-4H-4-hydroxy-6-methylthieno[2,3-b]thiopyran-2 sulfonamide(VI) To a suspension of product from example 3 (65 gm, 0.247 mole) in methanol (455 ml) sodium borohydride (7.03 gm, 0.185 mole) was added and the resulting mixture stirred for 2 hrs at 25 to 30*C. Methanol was concentrated from reaction mixture to get a sticky mass. Water (1000 ml) was added to the sticky mass and the mixture stirred for 0.5 hrs and the pH adjusted to 6.5 to 7.0 by acetic acid. Stirring was then done 1 hrs at 20 to 25*C. The product 12 WO 2006/070387 PCT/IN2004/000420 obtained was filtered and washed with water The cake was sucked to remove as much water as possible, and dried to get title compound (64.4 gm, 99 %). Example 5: Preparation of 5,6 dihydro-4H-4-hydroxy-6-methylthieno[2,3-b]thiopyran -2 sulfonamide-7,7 dioxide (VII) To a suspension of product from example 4 (64.4 gm, 0.242 mole) in Acetic acid (320ml) sodium perborate (83.48 gm, 0.545 mole) was added and resulting mixture stirred for 1 hr at 25 to 30'C, then heated to attain temperature 60 to 65*C and maintained for 3 hrs. Acetic acid was concentrated from reaction mixture to get a sticky mass, which was dissolved in water (400 ml). Product was extracted with ethyl acetate. Organic layer was concentrated to keep inside volume 100 ml and then cooled to 0 to 5'C and stirred for 2 hrs. The product was filtered and washed with chilled ethyl acetate. The cake was sucked to remove as much ethyl acetate as possible, and dried to get title compound (55 gm, 76.27%). 'H NMR (DMSO d-6) 5 1.49 (d,3H,CH 3 )- 2.42 (m,2H,CH 2 ) 3.55 (m,1H,6-H) 4.60-4.90 (m, 1H,4-H) 7.51 (bs,2H,NH 2 ) 7.69 (bs, 1H,3-H) Example 6: Preparation of 5,6 dihydro-4H-4-acetylamino-6-methylthieno[2,3-b]thiopyran-2 sulfonamide-7,7 dioxide(VIII) A solution of product from example 5 (55 gm, 0.185 mole) in acetonitrile (715ml) was cooled to 0 to 5*C and sulfuric acid (167.5 ml, 3.144 mole) added dropwise maintaining temperature 0 to 5*C. The temperature was allowed to rise to 25 to 30'C. The mixture was stirred for 25 to 27 hrs. The reaction mixture was added to mixture of water and ethyl acetate below 5'C and pH of reaction mixture was adjusted to 7.5 by 50% solution of sodium hydroxide. The sodium sulphate salt was filtered and washed with ethyl acetate. The organic layer was separated. Aqueous layer was extracted with ethyl acetate. The organic layer was concentrated to get sticky mass as title compound (VIII) (50 gm.91.6 %). 'H NMR (DMSO d-6) 5 1.47(d, 3H,CH 3 ) 1.96 & 2.01 (s,3H each, COCH 3 ) 2.30-2.60 (m,2H,CH 2 ) 3.70-3.85 (m,1H,CH) 5.20-5.30 (m,1H,CH) 7.44 & 7.88 (s, 2H,NH 2 ) 7.59 (s, 1H,3-H). Example 7: Preparation of 5,6 dihydro-4H-4-ethylamino-6-methylthieno[2,3-b]thiopyran-2 sulfonamide-7,7 dioxide(IX) To a solution of borane dimethyl sulfide complex (52.59 ml, 0.546 mole) and THF (108 ml) product from example 6 (50 gm, 0.148 mole) in THF (80 mole) was added at 0 to 5*C.The temperature was allowed to rise 25 to 30'C and mixture stirred for 10 hrs. The reaction mixture was added to I N sulfuric acid (190 ml) at 0 to 5*C and stirred for 1 hr. pH was adjusted to 7 with 50 % sodium hydroxide solution, and stirred for 1 hr and then product 13 WO 2006/070387 PCT/IN2004/000420 extracted with ethyl acetate. Ethyl acetate layer was concentrated to get sticky mass as title compound (IX) (39.5 gm, 82.41 %). Example 8: Preparation of Trans 5,6 dihydro-4H-4-ethylamino-6-methylthieno[2,3 b]thiopyran-2-sulfonamide-7,7 dioxide (X) A solution of product from example 7 (39.5 gm, 0.132 mole) in ethyl acetate (426 ml) was cooled to 0 to 5"C and ethanolic HCI (20 ml) was added and stirred for 3 hrs at 0 to 5*C. The product was precipitated out, filtered and washed with chilled ethyl acetate. The cake was sucked to remove as much ethyl acetate as possible, and dried to get compound (21 gm) The product was suspended into ethyl acetate (210 ml), refluxed for 1 hr, then cooled to 10*C. The product was filtered and washed with chilled ethyl acetate. The cake was sucked to remove as much ethyl acetate as possible, and dried to hydrochloride salt of title compound (18 gm). The salt was then treated with saturated solution of sodium bicarbonate and mixture extracted with ethyl acetate. The organic extract were dried, filtered and concentrated to dryness to yield title compound (X) (15 gm, 37.98 %). Example 9: Preparation of 5,6 dihydro-4H-4-(S)-ethylamino-6-(S)-methylthieno[2,3 b]thiopyran-2-sulfonamide-7,7 dioxide Hydrochloride(I) A mixture of compound from example 8 (15 gmO.0462 mole) and di-p-toluyl-D tartaric acid monohydrate (4.55 gm, 0.01125 mole) in n-propanol (1600 ml) was heated to boiling and hot solution filtered through a filter-aid pad with a layer of charcoal. The filtrate was concentrated by boiling to a volume of about (400ml) and then allowed to crystallize. After standing overnight the crystals were filtered off and material recrystallized twice more from n-propanol (400 ml) to yield a 2:1 salt of free base to acid. Combined mother liquors from this recrystallization were saved for stage B. The salt was then treated with a saturated solution of sodium bicarbonate and mixture extracted with ethyl acetate. The organic extract were dried, filtered and concentrated to dryness to yield (3.2gm) of freebase. The hydrochloride salt was prepared from 5.6 N HCl ethanol and crystallized from methanol isopropanol to yield (2.83 gm) of (+) isomer, SOR 8.23 (C 0.9 methanol) M.P. 283 -285*C. The combine mother liquor was treated with saturated solution of sodium bicarbonate and mixture extracted with ethyl acetate. The organic extracts were dried, filtered and concentrated to dryness. The residue was treated with di-p-toluyl-L-tartaric acid monohydrate (4.55 gm, 0.01125 mole) in n-propanol (1600 ml) and the isomer separated by the process described previously to give title compound (I) (3.75 gm, 22.48 %) SOR =-8.34 (C 1, Methanol) M.P. 283 to285*C. 14

Claims (33)

  1. 2. A process as claimed in claim 1 wherein in step (a), the organic solvent is selected from the group consisting of ethers, cyclic ethers and aromatic hydrocarbon.
  2. 3. A process as claimed in claim I wherein the organic solvent used in step (a) is tetrahydrofuran.
  3. 4. A process as claimed in claim I wherein step (a) is carried out in the presence of a base selected from the group consisting of organic alkylamine and pyridine.
  4. 5. A process as claimed in claim 1 wherein the base is trialkyl amine.
  5. 6. A process as claimed in claim 1 wherein the base is triethyl amine.
  6. 7. A process as claimed in claim 1 wherein in compound of formula II, X is a halo selected from the group consisting of Cl, Br and I.
  7. 8. A process as claimed in claim 1 wherein step (a) is carried out at a temperature in the range of 0*C to 70*C.
  8. 9. A process as claimed in claim 1 wherein in step (b), the organic solvent is an aprotic non-polar solvent.
  9. 10. A process as claimed in claim 9 wherein the aprotic non-polar solvent used is a chlorinated solvent.
  10. 11. A process as claimed in claim 10 wherein the chlorinated solvent is MDC.
  11. 12. A process as claimed in claim 1 wherein the Lewis acid used in step (b) is selected from the group consisting of AlCl 3 , ZnCl 2 and SnCl 4 .
  12. 13. A process as claimed in claim 1 wherein the Lewis acid in step (b) is SnCl 4 .
  13. 14. A process as claimed in claim 1 wherein the sulfonyl chloride of formula XX is dissolved in step (c) in an organic solvent selected from the group consisting of ether and ketone.
  14. 15. A process as claimed in claim I used in step (c) wherein the organic solvent is tetrahydrofuran.
  15. 16. A process as claimed in claim 1 wherein in step (c) the sulfonyl chloride of formula XX is dissolved in an organic sovlent and then treated with ammonia followed by chlorination with a chlorinating agent selected from the group consisting of POCl 3 , PCl 5 , PCl 3 and SOCl 2 and in the presence of a chlorination solvent selected from the group consisting of CHC1 3 , MDC, and EDC.
  16. 17. A process as claimed in claim 16 wherein the chlorinating agent is SOCl 2 .
  17. 18. A process as claimed in claim 16 wherein the chlorination solvent is MDC. 17 WO 2006/070387 PCT/IN2004/000420
  18. 19. A process as claimed in claim I wherein in step (d) reduction is effected using sodium borohydride in the presence of a solvent and at a temperature in the range of O'C to 40*C.
  19. 20. A process as claimed in claim 19 wherein the solvent is a lower aliphatic alcohol.
  20. 21. A process as claimed in claim 20 wherein the lower aliphatic alcohol is methanol.
  21. 22. A process as claimed in claim I wherein in step (e) compound of formula VI is oxidised with sodium perborate in presence of acetic acid at 20*C to 70*C.
  22. 23. A process as claimed in claim 1 wherein in step (f) the Ritter reaction of compound of formula VII is effected in a strong acid with acetonitrile at 10*C to 40C.
  23. 24. A process as claimed in claim 23 wherein the strong acid is selected from the group consisting of sulfuric acid and a mixture of concentrated sulfuric acid and fuming sulfuric acid.
  24. 25. A process as claimed in claim 1 wherein in step (g), reduction is effected using borane dimethylsulfide complex in an organic solvent selected from ether and cyclic ether.
  25. 26. A process as claimed in claim 1 wherein the organic solvent used in step (g) is tetrahydrofuran.
  26. 27. A process as claimed in claim 1 wherein in step (h), the organic solvent is selected from the group consisting of a ketone, an ester, a dipolar aprotic solvent, lower aliphatic alcohol, aliphatic hydrocarbon and aromatic hydrocarbon.
  27. 28. A process as claimed in claim 27 wherein the ester is ethyl acetate.
  28. 29. A process as claimed in claim 1 wherein the acid used for salt formation in step (h) is a mineral acid selected from the group consisting of HCl, H 2 S0 4 , HNO 3 , and HBr dissolved in a lower aliphatic alcohol.
  29. 30. A process as claimed in claim 29 wherein the acid is ethanolic HCl.
  30. 31. A process as claimed in claim 1 wherein the organic solvent used for recrystallization in step (h) is selected from the group consisting of a ketone, an ester, a dipolar aprotic solvent, lower aliphatic alcohol, aliphatic hydrocarbon and aromatic hydrocarbon.
  31. 32. A process as claimed in claim 31 wherein the organic solvent is selected from an ester, lower aliphatic alcohol and mixture thereof
  32. 33. A process as claimed in claim 32 wherein the organic solvent is selected from ethyl acetate, ethanol and mixture thereof
  33. 34. A process as claimed in claim 1 wherein the compound of formula X is resolved using di-p-toluyl-L-tartarate and di-p-toluyl-D-tartarate. 18
AU2004326111A 2004-12-28 2004-12-28 Process for preparing 5,6-dihydro-4-(S)-(ethylamino)-6-(S) methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide HCI Abandoned AU2004326111A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2004/000420 WO2006070387A1 (en) 2004-12-28 2004-12-28 PROCESS FOR PREPARING 5,6-DIHYDRO-4-(S)-(ETHYLAMINO)-6-(S) METHYL-4H-THIENO[2,3b]THIOPYRAN-2-SULPHONAMIDE-7,7-DIOXIDE HCI

Publications (1)

Publication Number Publication Date
AU2004326111A1 true AU2004326111A1 (en) 2006-07-06

Family

ID=34960556

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004326111A Abandoned AU2004326111A1 (en) 2004-12-28 2004-12-28 Process for preparing 5,6-dihydro-4-(S)-(ethylamino)-6-(S) methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide HCI

Country Status (5)

Country Link
EP (1) EP1841774A1 (en)
AU (1) AU2004326111A1 (en)
BR (1) BRPI0419257A (en)
MX (1) MX2007007923A (en)
WO (1) WO2006070387A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1838717A2 (en) * 2005-01-18 2007-10-03 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Amorphous and crystalline forms of dorzolamide hydrochloride and processes of making same
JP6013379B2 (en) 2011-03-10 2016-10-25 ザック システム エス.ピー.エー.ZaCh System S.p.A. Asymmetric reduction method
ITMI20121165A1 (en) * 2012-07-03 2014-01-04 Zach System Spa ASYMMETRICAL REDUCTION PROCESS
CN111233887A (en) * 2018-11-28 2020-06-05 武汉武药科技有限公司 Synthesis process of dorzolamide hydrochloride intermediate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863922A (en) * 1984-12-12 1989-09-05 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use
US5157129A (en) * 1990-04-18 1992-10-20 Merck & Co., Inc. Enantiospecific synthesis of s-(+)-5,6-dihydro-4-(r-amino)-4h-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide
TW265343B (en) * 1993-03-22 1995-12-11 Merck & Co Inc

Also Published As

Publication number Publication date
BRPI0419257A (en) 2008-05-06
WO2006070387A1 (en) 2006-07-06
EP1841774A1 (en) 2007-10-10
MX2007007923A (en) 2007-11-14

Similar Documents

Publication Publication Date Title
EP1740593B1 (en) Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form i
ES2388371T3 (en) N- {1- [3- (2-ethoxy-5- (4-ethylpiperazinyl) benzenesulfonyl) -4,5-dihydro-5-oxo-1,2,4-triazin-6-yl] ethyl} -butyramide, method of preparation and use
CA2119218C (en) Enantioselective synthesis of 5,6-dihydro-(s)-4-(ethylamino)-(s)-6-methyl-4h-thieno 2,3-b thiopyran-2-sulfonamide 7,7-dioxide and related compounds
CA2040604A1 (en) Enantiospecific synthesis of s-(+)-5,6-dihydro-4-(r-amino)-4h-thieno[2,3-b] thiopyran-2-sulfonamide-7,7-dioxide
WO2022165148A1 (en) Mk2 inhibitors, the synthesis thereof, and intermediates thereto
KR20050061490A (en) Process and intermediates for the preparation of thienopyrrole derivatives
WO1996030374A1 (en) Process for preparing olanzapine
US7109353B2 (en) Process for preparing 5,6-dihydro-4-(S)-(ethylamino)-6-(S) methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide HCl
AU2004326111A1 (en) Process for preparing 5,6-dihydro-4-(S)-(ethylamino)-6-(S) methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide HCI
CN109867684A (en) A kind of preparation method of II type bisulfate clopidogrel
CN112645863B (en) Dipyrromethene-1-ketone compound and preparation method thereof
EP0000301B1 (en) Process for the preparation of thieno(2,3-c) and thieno(3,2-c) pyridines
CA2218654C (en) Synthesis of (s)-3-(2-thienylthio) butyric acid and analogs
KR20070053697A (en) Improved process for the manufacture of mirtazapine
CN111689969A (en) Preparation method of sildenafil
KR100377782B1 (en) A process for preparing pyrazolopyrimidinone derivatives for the treatment of impotence
CN111039963B (en) WXFL10203614 water-soluble analogue and synthetic method thereof
SU1192623A3 (en) Method of producing esters
KR20070113197A (en) Process for preparing 5,6-dihydro-4-(s)-(ethylamino)-6-(s)methyl-4h-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide hcl
KR101170192B1 (en) One-pot process for producing 1,2-benzisoxazole-3-methanesulfonamide
JP2002053580A (en) Method for manufacturing tricyclic compound
JPH0667942B2 (en) Tetrahydro tricyclic compound
JP2007516166A (en) Preparation of amorphous form of platelet aggregation inhibitor
KR100241089B1 (en) Novel process for preparation of 2-mercapto-4-methyl-1,3-thiazole-5-acetic acid
JPH0495094A (en) Synthesis of benzopyrano(2,3-b)pyridine derivative

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period